Q1 Earnings Estimate for Longeveron Issued By Zacks Research

Longeveron Inc. (NASDAQ:LGVN) – Equities researchers at Zacks Research raised their Q1 2026 earnings per share estimates for Longeveron in a report released on Tuesday, March 10th. Zacks Research analyst B. Sorensen now forecasts that the company will post earnings per share of ($0.23) for the quarter, up from their prior estimate of ($1.84). The consensus estimate for Longeveron’s current full-year earnings is ($3.69) per share. Zacks Research also issued estimates for Longeveron’s Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.19) EPS, FY2026 earnings at ($0.83) EPS, FY2027 earnings at ($1.24) EPS and FY2028 earnings at ($1.19) EPS.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Longeveron in a research note on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $6.50.

Longeveron Price Performance

Shares of NASDAQ LGVN opened at $0.81 on Thursday. The company has a market cap of $17.33 million, a price-to-earnings ratio of -0.77 and a beta of 0.23. The stock’s 50-day moving average is $0.57 and its two-hundred day moving average is $0.67. Longeveron has a 1-year low of $0.48 and a 1-year high of $1.92.

Hedge Funds Weigh In On Longeveron

A hedge fund recently bought a new stake in Longeveron stock. XTX Topco Ltd bought a new stake in Longeveron Inc. (NASDAQ:LGVN) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned about 0.32% of Longeveron at the end of the most recent reporting period. Institutional investors and hedge funds own 10.01% of the company’s stock.

Longeveron Company Profile

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.